Table 3.
List of reported small-cell transformations resistant to crizotinib/alectinib/ceritinib/lorlatinib
| Study | Cha et al6 | Takegawa et al7 | Fujita et al8 | Miyamoto et al9 | Caumont et al10 | Levacq et al11 |
|---|---|---|---|---|---|---|
| Ethnicity | Korean | Japanese | Japanese | Japanese | French | Belgian |
| Age (years) | 72 | 43 | 67 | 58 | 63 | 53 |
| Gender | Male | Female | Female | Female | Female | Female |
| Smoking history | 40 pack-years | NA | Never smoker | Never smoker | Never smoker | Never smoker |
| CNS metastasis present | No | Yes | Yes | No | Yes | No |
| Resistance to most immediate prior crizotinib/alectinib/ceritinib/lorlatinib | Crizotinib | Alectinib (also crizotinib prior to alectinib) | Alectinib (also crizotinib prior to alectinib) | Alectinib (also crizotinib prior to alectinib) | Crizotinib | Ceritinib (also crizotinib prior to certinib) |
| Subsequent SCLC therapy | NA | None | Alectinib + irinotecan (with PR) | Cisplatin/irinotecan | NA | Cisplatin/etoposide followed by CAV |
|
| ||||||
| Study | Ou et al12 | 8 (present case) | ||||
|
| ||||||
| Ethnicity | American | Chinese | ||||
| Age (years) | 35 | 49 | ||||
| Gender | Male | Male | ||||
| Smoking history | Never smoker | Never smoker | ||||
| CNS metastasis present | Yes | Yes | ||||
| Resistance to most immediate prior crizotinib/alectinib/ceritinib/lorlatinib | Lorlatinib (also prior ceritinib to alectinib) | Crizotinib | ||||
| First-line treatment assessment | Carboplatin/etoposide + alectinib | Etoposide | ||||
Abbreviations: CAV, chemotherapy regimen (cyclophosphamide + doxorubicin + vincristine); CNS, central nervous system; PR, partial response; SCLC, small-cell lung cancer; NA, not available.